Back to results
US 2025/0144022 A1Published application
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFAlpha ANTIBODY
AssigneeAprogen, Inc.
InventorsMijeong PARK, Seok Min JIN
Life of this patent
Estimating the term…
Abstract
Provided is a stable pharmaceutical composition containing an anti-TNFα antibody. The pharmaceutical composition is characterized by being stable while containing a high concentration of the anti-TNFα antibody.
Claims15
A pharmaceutical composition, comprising:
- 80 mg/ml to 200 mg/ml of an anti-TNFα antibody;
- a buffer;
- an excipient;
- and
- a surfactant, and
- having a pH of 4 to 7.5,
- wherein,
- the buffer comprises at least one selected from the group consisting of succinate, phosphate, acetate, and pharmaceutically acceptable salts thereof,
- the excipient comprises at least one selected from the group consisting of mannitol, glycerol, glycine, and pharmaceutically acceptable salts thereof, and
- the surfactant comprises polysorbate 20.
7 more elements
A method for producing a stable liquid formulation of an anti-TNFα antibody, the method comprises a step of mixing
- 80 mg/ml to 200 mg/ml of the anti-TNFα antibody;
- a buffer;
- an excipient;
- and
- a surfactant to prepare an aqueous liquid composition,
- wherein,
- the buffer comprises at least one selected from the group consisting of succinate, phosphate, acetate, and pharmaceutically acceptable salts thereof,
- the excipient comprises at least one selected from the group consisting of mannitol, glycerol, glycine, and pharmaceutically acceptable salts thereof,
- the surfactant comprises polysorbate 20, and
- the aqueous liquid composition has a pH of 4 to 7.5.
7 more elements
A method for enhancing stability of an anti-TNFα antibody in a liquid formulation, the method comprising a step of mixing:
- 80 mg/ml to 200 mg/ml of the anti-TNFα antibody;
- a buffer;
- an excipient;
- and
- a surfactant to prepare an aqueous liquid composition,
- wherein,
- the buffer comprises at least one selected from the group consisting of succinate, phosphate, acetate, and pharmaceutically acceptable salts thereof,
- the excipient comprises at least one selected from the group consisting of mannitol, glycerol, glycine, and pharmaceutically acceptable salts thereof,
- the surfactant comprises polysorbate 20, and
- the aqueous liquid composition has a pH of 4 to 7.5.
7 more elements
Dependencies are inferred from the claim text.